Warner-Lambert 4Q Net 40c/Diluted Share Vs 28c
Dow Jones Newswires
Warner-Lambert Co. - Morris Plains, NJ
4th Quar Dec. 31:
1998 1997
Sales $2,877,900,000 $2,327,400,000
Net income 341,100,000 235,700,000
Shr earns (basic)
Net income .42 .29
Shr earns (diluted)
Net income .40 .28
Per share figures reflect a 3-for1 stock split effective May 8, 1998.
Year Dec. 31:
1998 1997
Sales $10,213,700,000 $8,179,800,000
Net income 1,254,000,000 869,500,000
Shr earns (basic)
Net income 1.53 1.07
Shr earns (diluted)
Net income 1.48 1.04
Per share amounts reflect a 3-for-1 stock split effective May 8, 1998.
Warner-Lambert Co. (WLA) said worldwide sales for the year increased 25% to a record $10.2
billion compared with $8.2 billion in 1997. After adjusting for the unfavorable effects of exchange,
sales increased 28%. Unit volume growth for the year was 29%.
The company said that "based on current planning assumptions, we are confident that we will
realize an increase in diluted earnings per share of 30% in 1999."
Warner-Lambert Co. said for the year, worldwide sales in the pharmaceutical segment, the largest
of Warner-Lambert's three business segments, increased 55% to $5.6 billion compared with $3.6
billion in 1997. At constant foreign exchange rates, sales rose 57%.
In the U.S., worldwide sales sales rose 74% to $3.8 billion. In markets outside the U.S., sales
increased 26% - 32% at constant foreign exchange rates - to $1.8 billion.
The company said pharmaceutical sales growth was led by Lipitor (atorvastatin calcium).
Worldwide sales of Lipitor more than doubled to $2.2 billion in 1998.
The company said its oral agent for the treatment of type 2 diabetes, ReZulin (troglitazone) helped
pharmaceutical sales for the year. Sales rose 78% to $748 million; sales of anticonvulsant,
Neurontin (gabapentin), grew 76% to $514 million; and sales of the antihypertensive Accupril
(quinapril), increased 20% to $454 million.
Warner-Lambert Co. said for the year, worldwide sales in the pharmaceutical segment, the largest
of Warner-Lambert's three business segments, increased 55% to $5.6 billion compared with $3.6
billion in 1997. At constant foreign exchange rates, sales rose 57%.
In the U.S., worldwide sales sales rose 74% to $3.8 billion. In markets outside the U.S., sales
increased 26% - 32% at constant foreign exchange rates - to $1.8 billion.
The company said pharmaceutical sales growth was led by Lipitor (atorvastatin calcium).
Worldwide sales of Lipitor more than doubled to $2.2 billion in 1998.
The company said its oral agent for the treatment of type 2 diabetes, ReZulin (troglitazone) helped
pharmaceutical sales for the year. Sales rose 78% to $748 million; sales of anticonvulsant,
Neurontin (gabapentin), grew 76% to $514 million; and sales of the antihypertensive Accupril
(quinapril), increased 20% to $454 million.
|
